Therapeutic targeting and patient selection for cancers with homologous recombination defects
Open Access
- 2 May 2017
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 12 (6) , 565-581
Abstract
Introduction: DNA double-strand breaks (DSBs) are toxic DNA lesions that can be repaired by non-homologous end-joining (NHEJ) or homologous recombination (HR). Mutations in HR genes elicit a predisposition to cancer; yet, they also result in increased sensitivity to certain DNA damaging agents and poly (ADP-ribose) polymerase (PARP) inhibitors. To optimally implement PARP inhibitor treatment, it is important that patients with HR-deficient tumors are adequately selected. Areas covered: Herein, the authors describe the HR pathway mechanistically and review the treatment of HR-deficient cancers, with a specific focus on PARP inhibition for BRCA1/2-mutated breast and ovarian cancer. In addition, mechanisms of acquired PARP inhibitor resistance are discussed. Furthermore, combination therapies with PARP inhibitors are reviewed, in the context of both HR-deficient and HR-proficient tumors and methods for proper patient selection are also discussed. Expert opinion: Currently, only patients with germline or somatic BRCA1/2 mutations are eligible for PARP inhibitor treatment and only a proportion of patients respond. Patients with HR-deficient tumors caused by other (epi)genetic events may also benefit from PARP inhibitor treatment. Ideally, selection of eligible patients for PARP inhibitor treatment include a functional HR read-out, in which cancer cells are interrogated for their ability to perform HR repair and maintain replication fork stability.Keywords
Funding Information
- H2020 European Research Council (ERC Consolidator Grant 682421)
- KWF Kankerbestrijding (Alpe d'HuZes grant number 7048, RUG2011-5093)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO-VIDI 91713334)
This publication has 173 references indexed in Scilit:
- BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group StudyBritish Journal of Cancer, 2013
- RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break ResectionMolecular Cell, 2013
- Plk1 and CK2 Act in Concert to Regulate Rad51 during DNA Double Strand Break RepairMolecular Cell, 2012
- Double-Strand Break Repair-Independent Role for BRCA2 in Blocking Stalled Replication Fork Degradation by MRE11Cell, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Pathology of hereditary breast cancerCellular Oncology, 2011
- 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA BreaksCell, 2010
- A Selective Requirement for 53BP1 in the Biological Response to Genomic Instability Induced by Brca1 DeficiencyMolecular Cell, 2009
- Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancerInternational Journal of Cancer, 2002
- Identification of the breast cancer susceptibility gene BRCA2Nature, 1995